Opinion on Biotechnology

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HGS: good news for genomics companies

Published By Datamonitor
14 Sep 2000
Expert View
Expert View

The monoclonal model of drug development

Published By Datamonitor
15 Sep 2000
CommentWire
CommentWire

Antisoma: rollercoaster ride

Published By Datamonitor
19 Sep 2000
CommentWire
CommentWire

Eli Lilly: cheeky but risky insulin strategy

Published By Datamonitor
19 Sep 2000
Expert View
Expert View

Waste not, want not: drug delivery to the rescue

Published By Datamonitor
22 Sep 2000
CommentWire
CommentWire

Cell Pathways: FDA rejection could spell trouble

Published By Datamonitor
25 Sep 2000
CommentWire
CommentWire

Scotia: Foscan falters at the final hurdle

Published By Datamonitor
27 Sep 2000
CommentWire
CommentWire

Serono: fertile market for Ovidrel

Published By Datamonitor
03 Oct 2000
CommentWire
CommentWire

Alza: a new focus on in-house development

Published By Datamonitor
06 Oct 2000
Expert View
Expert View

From pens to transplants: what next for insulin?

Published By Datamonitor
06 Oct 2000

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.